Program
Vancomycin
Also written as “Vancomycin inhalation powder”, “vancomycin” and “Vancomycin Hydrochloride for Injection (IA)”.
Its studies are mostly in Cystic Fibrosis · Melanoma · Conjunctivitis, Bacterial · Endocarditis, Bacterial · Cellulitis, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 40 open or running | phase 4since Dec 11, 2007 | May 3, 2002 | none ahead |
| Savara | 20 open or running | phase 3since Jun 1, 2017 | Dec 6, 2012 | none ahead |
| Kurobe | 10 open or running | phase 3since Apr 29, 2015 | Apr 29, 2015 | none ahead |
| Osteal Therapeutics | 10 open or running | phase 2since Oct 17, 2018 | Oct 17, 2018 | none ahead |
Also a collaborator on its studies: Merck and synteract-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 3, 2002First studies: 2 phase 3 studiesNew to PfizerPfizer · NCT00035425, NCT00037050
- Apr 15, 2005Phase 3 study in BacteremiaPfizer · NCT00108433 · 61 enrolled · United States, Colombia, India and more
- Dec 11, 2007Phase 4 study in Pneumonia, Ventilator-AssociatedPfizer · NCT00572559 · 149 enrolled · United States, Puerto Rico
- Dec 6, 2012Savara's first study: phase 2 study in Cystic FibrosisNew to SavaraSavara · NCT01746095 · 87 enrolled · United States
- Apr 29, 2015Kurobe's first study: phase 3 study in Conjunctivitis, BacterialNew to KurobeKurobe · NCT02432807 · 303 enrolled · United States
- Jun 1, 2017Phase 3 study in Cystic FibrosisSavara · NCT03181932 · 188 enrolled · United States, Canada
- Oct 17, 2018Osteal Therapeutics's first study: phase 2 study in Prosthetic Joint InfectionNew to Osteal TherapeuticsOsteal Therapeutics · NCT03721328 · 15 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Peptidoglycan inhibitor; Peptidoglycan inhibitor”ChEMBL 37, by rule
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT03721328Prosthetic Joint Infection · United States | 2 | Completed | Osteal Therapeutics | Aug 25, 2020 | 15 |
| NCT03181932Cystic Fibrosis · United States, Canada | 3 | Completed | Savara | Jul 28, 2020 | 188 |
| NCT02432807Conjunctivitis, Bacterial · United States | 3 | Completed | Kurobe | May 31, 2018 | 303 |
| NCT01746095Cystic Fibrosis · United States | 2 | Completed | Savara | Nov 2014 | 87 |
| NCT00572559Pneumonia, Ventilator-Associated · United States, Puerto Rico | 4 | Completed | Pfizer | 149 | |
| NCT00108433Bacteremia · United States, Colombia, India and more | 3 | Terminated | Pfizer | 61 | |
| NCT00037050Bacterial Infections | 3 | Completed | Pfizer | 739 | |
| NCT00035425Febrile Neutropenia · United States, Argentina, Brazil and more | 3 | Completed | Pfizer | 120 |
How it is read
Names in the registry
- “Vancomycin”, 6 entries
- “Vancomycin inhalation powder”, 2 entries
- “vancomycin”, 2 entries
- “Vancomycin Hydrochloride for Injection (IA)”, 1 entry
- “Vancomycin Hydrochloride for Injection (IV)”, 1 entry
Conditions, from the studies’ own filings
- Cystic Fibrosis, 2 studies
- Melanoma, 1 study
- Conjunctivitis, Bacterial, 1 study
- Endocarditis, Bacterial, 1 study
- Cellulitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.